Superworth

Seer SEER

Medical - Diagnostics & Research, Healthcare
$1.73
+2.98%
Market cap
$95.8M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
6.7×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$14.2M
−13% on a year ago
Net margin
n/m
outside −100% to 100%
Free cash flow yield
−46.2%

Seer trades at 6.7× sales. Its trailing earnings are negative, so it has no PE. Revenue was $14.2M over the last twelve months, down 13% on a year earlier.

Charts

Financials

Income statement for SEER, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$4.2M+5%$4.4M−4%$3.1M−24%$3.1M−23%$4M−3%$4M−10%$4.2M+37%$4.1M+32%$4.1M+2%$4.2M+5%$2.8M−34%$3.1M−23%
Cost of revenue$2M−0%$2.4M+6%$1.7M−14%$1.3M−22%$2.1M+4%$2M−19%$2.1M+26%$1.9M+45%$2M−4%$2M+2%$1.8M−16%$1.6M−18%
Gross profit$2.2M+11%$2M−13%$1.4M−34%$1.7M−24%$1.9M−10%$2M+1%$2.1M+51%$2.1M+22%$2.1M+9%$2.2M+8%$982K−52%$1.5M−29%
R&D$13.2M+14%$11.2M−12%$12.3M−15%$12.7M−10%$13M−2%$12.6M+13%$11.3M−8%$12M−6%$10.8M−17%$9.7M−23%$8.8M−22%$8.2M−32%
SG&A$14.8M−4%$13.1M−11%$14.3M−5%$16.1M+0%$13.3M−10%$12.9M−1%$11.4M−20%$10.7M−34%$10.7M−20%$9.8M−24%$9.4M−18%$10.1M−5%
−$25.8M+3%−$22.2M−11%−$25.2M−8%−$27.1M−3%−$24.3M−6%−$23.5M+6%−$20.7M−18%−$20.5M−24%−$19.3M−21%−$17.4M−26%−$17.3M−17%−$16.8M−18%
Pre-tax incomen/an/a−$20.7M−$22.9M−$21.3M−$21.6M−$19.8M−4%−$19.4M−15%−$18.2M−15%−$16M−26%−$16.8M−15%−$16.9M−13%
n/an/a$0$0$0$98K$101K$48K$24K$28K−71%$10K−90%$9K−81%
Net income−$21.1M−12%−$17.8M−21%−$20.7M−14%−$22.9M−3%−$21.3M+1%−$21.7M+22%−$19.9M−4%−$19.4M−15%−$18.2M−15%−$16M−26%−$16.8M−16%−$16.9M−13%
−$0.33−13%−$0.28−22%−$0.32−16%−$0.35−5%−$0.35+6%−$0.37+32%−$0.34+6%−$0.33−6%−$0.32−9%−$0.29−22%−$0.30−12%−$0.31−6%
63.9M+2%64.2M+2%64.6M+2%64.6M+1%61.2M−4%59.1M−8%59.4M−8%58.1M−10%56.3M−8%56M−5%56M−6%55.2M−5%

Cost of revenue: Q1 FY20: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY20: 6 months less the 3 months printed beside them.

EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Seer's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
SEERSeer$95.8Mn/mn/a6.7×−13%n/m
ICCCImmucell$95.9M132×44.1×3.1×+8%2.6%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
ATNMActinium Pharmaceuticals$45M4.0×3.3×n/mn/mn/m
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
ELMDElectromed$223.9M20.4×29.0×3.0×+15%15.3%
Peer median$96.3M12.8×18.0×1.3×+7%6.8%

More on Seer

Each number over time

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .